First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation

著录项

• 来源
  《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) 》 |2016年第null期| 共1页
• 作者

  Kim R.; Sharma S.; Meyer T.; Sarker D.; Macarulla T.; Sung M.; Choo S. P.; Shi H.; Schmidt-Kittlers O.; Clifford C.; Wolf B.; Llovet J. M.;

  展开▼
• 作者单位

  H Lee Moffitt Canc Ctr &

  Res Inst Gastrointestinal Oncol Tampa FL USA;

  Huntsman Canc Inst Internal Med Salt Lake City UT USA;

  UCL Canc Inst Oncol London England;

  Guys Hosp Early Phase Trials Unit London England;

  Vall dHebron Univ Hosp Med Oncol Barcelona Spain;

  Icahn Sch Med Mt Sinai Tisch Canc Inst New York NY 10029 USA;

  Natl Canc Ctr Singapore Med Oncol Singapore Singapore;

  BluePrint Med Clin Dev Cambridge MA USA;

  BluePrint Med Clin Dev Cambridge MA USA;

  BluePrint Med Clin Dev Cambridge MA USA;

  BluePrint Med Clin Dev Cambridge MA USA;

  Icahn Sch Med Mt Sinai Tisch Canc Inst New York NY 10029 USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 肿瘤学 ;
• 关键词